SUNPHARMA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.7
| Stock Code | SUNPHARMA | Market Cap | 4,37,939 Cr. | Current Price | 1,825 ₹ | High / Low | 1,917 ₹ |
| Stock P/E | 146 | Book Value | 93.2 ₹ | Dividend Yield | 0.88 % | ROCE | 14.8 % |
| ROE | 12.8 % | Face Value | 1.00 ₹ | DMA 50 | 1,795 ₹ | DMA 200 | 1,745 ₹ |
| Chg in FII Hold | -0.18 % | Chg in DII Hold | 0.28 % | PAT Qtr | 609 Cr. | PAT Prev Qtr | 872 Cr. |
| RSI | 55.7 | MACD | 0.56 | Volume | 30,38,183 | Avg Vol 1Wk | 19,66,578 |
| Low price | 1,547 ₹ | High price | 1,917 ₹ | PEG Ratio | -39.9 | Debt to equity | 0.61 |
| 52w Index | 75.0 % | Qtr Profit Var | -70.2 % | EPS | 10.9 ₹ | Industry PE | 32.1 |
📊 SUNPHARMA (Sun Pharmaceutical Industries Ltd.) trades at a steep premium with a P/E of 146 compared to the industry average of 32.1. While ROCE (14.8%) and ROE (12.8%) are decent, the PEG ratio (-39.9) signals valuation concerns. Dividend yield of 0.88% provides minimal income support. Recent PAT decline (₹872 Cr → ₹609 Cr) raises caution on earnings consistency.
💡 Entry Price Zone: Current price ₹1,825 is near the 50 DMA (₹1,795) and above the 200 DMA (₹1,745). Ideal entry lies between ₹1,700–₹1,780, with deeper value accumulation possible around ₹1,600–₹1,650 if market weakness persists.
📈 Exit Strategy / Holding Period: For existing holders, SUNPHARMA remains a long-term play in the pharma sector but valuations are stretched. Hold for 3–5 years only if earnings growth stabilizes. Consider partial profit booking near ₹1,900–₹1,950 resistance levels. Monitor debt-to-equity (0.61) and quarterly profit trends closely.
Positive ✅
- 📌 Strong ROCE (14.8%) and ROE (12.8%) support efficiency.
- 📌 Dividend yield of 0.88% provides modest income stability.
- 📌 RSI at 55.7 indicates neutral momentum.
- 📌 EPS of ₹10.9 supports valuation strength.
Limitation ⚠️
- 📌 Extremely high P/E ratio of 146 compared to industry average (32.1).
- 📌 Negative PEG ratio (-39.9) highlights valuation risk.
- 📌 Sequential decline in PAT (₹872 Cr → ₹609 Cr).
Company Negative News 📉
- 📌 Quarterly profit decline (-70.2% variation).
- 📌 Reduction in FII holdings (-0.18%).
Company Positive News 📈
- 📌 Increase in DII holdings (+0.28%).
- 📌 Stable EPS despite profit decline.
Industry 🌐
- 📌 Industry P/E at 32.1 suggests sector is moderately valued.
- 📌 Pharma sector benefits from global demand for generics and specialty drugs.
Conclusion 💊
SUNPHARMA is a strong pharma player but trades at stretched valuations. Entry between ₹1,700–₹1,780 offers better risk-reward. Hold for 3–5 years with partial exits near ₹1,900–₹1,950. Long-term sustainability depends on stabilizing earnings growth and maintaining efficiency metrics.
Would you like me to expand this into a peer comparison to benchmark SUNPHARMA against other leading pharma companies?